HTG Molecular Diagnostics, Inc. – NASDAQ:HTGM
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
HTG Molecular Diagnostics stock price monthly change
-29.79%
month
HTG Molecular Diagnostics stock price quarterly change
-41.43%
quarter
HTG Molecular Diagnostics stock price yearly change
+279.63%
year
HTG Molecular Diagnostics key metrics
Market Cap | 1.06M |
Enterprise value | 1.41M |
P/E | -0.09 |
EV/Sales | 0.36 |
EV/EBITDA | -0.04 |
Price/Sales | 0.48 |
Price/Book | 0.18 |
PEG ratio | N/A |
EPS | -18.89 |
Revenue | 6.21M |
EBITDA | -19.28M |
Income | -20.15M |
Revenue Q/Q | -12.82% |
Revenue Y/Y | -28.20% |
Profit margin | -865.32% |
Oper. margin | -1112.8% |
Gross margin | -95.89% |
EBIT margin | -1112.8% |
EBITDA margin | -310.41% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHTG Molecular Diagnostics stock price history
HTG Molecular Diagnostics stock forecast
HTG Molecular Diagnostics financial statements
| Jun 2022 | 1.49M | -5.88M | -394.76% |
|---|---|---|---|
| Sep 2022 | 1.25M | -4.51M | -361.04% |
| Dec 2022 | 2.43M | -4.69M | -192.37% |
| Mar 2023 | 1.03M | -5.05M | -489.56% |
| Jun 2022 | 22205469 | 16.63M | 74.92% |
|---|---|---|---|
| Sep 2022 | 13610303 | 12.40M | 91.12% |
| Dec 2022 | 17777655 | 12.38M | 69.67% |
| Mar 2023 | 10865628 | 10.39M | 95.63% |
| Jun 2022 | -5.84M | -1.41M | -1.58M |
|---|---|---|---|
| Sep 2022 | -4.59M | 5.14M | -3.07M |
| Dec 2022 | -2.02M | 3.3M | 7.70M |
| Mar 2023 | -4.36M | -3.54M | -1.31M |
HTG Molecular Diagnostics alternative data
| Aug 2023 | 53 |
|---|---|
| Sep 2023 | 53 |
| Oct 2023 | 53 |
| Nov 2023 | 53 |
| Dec 2023 | 53 |
| Jan 2024 | 53 |
| Feb 2024 | 53 |
| Mar 2024 | 53 |
| Apr 2024 | 53 |
| May 2024 | 53 |
| Jun 2024 | 53 |
| Jul 2024 | 53 |
HTG Molecular Diagnostics other data
1.05%
-0.74%
of HTGM is owned by hedge funds
9.34K
-7.17K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 888 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BARAT STEPHEN officer: Senior VP of Therapeut.. | Common Stock | 888 | $0.8 | $710 | ||
Purchase | LYTTON LAURENCE W 10 percent owner | Series A Convertible Preferred Stock | 289 | N/A | N/A | ||
Sale | JOHNSON TIM B director, officer: Executive Ch.. | Common Stock | 5,718 | $0.72 | $4,111 | ||
Sale | MCMEANS SHAUN D officer: SVP, Fin.. | Common Stock | 945 | $2.11 | $1,992 | ||
Sale | MCMEANS SHAUN D officer: SVP, Fin.. | Common Stock | 945 | $2.26 | $2,136 | ||
Purchase | QIAGEN NV 10 percent owner | Common Stock | 753,012 | $3.98 | $3,000,000 | ||
Sale | MCMEANS SHAUN D officer: SVP, Fin.. | Common Stock | 946 | $2.27 | $2,148 | ||
Sale | NOVO HOLDINGS A/S 10 percent owner | COMMON STOCK | 720,214 | $1.75 | $1,260,375 | ||
Sale | NOVO HOLDINGS A/S 10 percent owner | COMMON STOCK | 382,437 | $1.91 | $730,072 | ||
Sale | NOVO HOLDINGS A/S 10 percent owner | COMMON STOCK | 47,162 | $2.02 | $95,456 |
| Quarter | Transcript |
|---|---|
| Q2 2022 11 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 12 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 29 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 10 Nov 2021 | Q3 2021 Earnings Call Transcript |
-
When is HTG Molecular Diagnostics's next earnings date?
Unfortunately, HTG Molecular Diagnostics's (HTGM) next earnings date is currently unknown.
-
Does HTG Molecular Diagnostics pay dividends?
No, HTG Molecular Diagnostics does not pay dividends.
-
How much money does HTG Molecular Diagnostics make?
HTG Molecular Diagnostics has a market capitalization of 1.06M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 28.52% to 6.37M US dollars.
-
What is HTG Molecular Diagnostics's stock symbol?
HTG Molecular Diagnostics, Inc. is traded on the NASDAQ under the ticker symbol "HTGM".
-
What is HTG Molecular Diagnostics's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of HTG Molecular Diagnostics?
Shares of HTG Molecular Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are HTG Molecular Diagnostics's key executives?
HTG Molecular Diagnostics's management team includes the following people:
- Mr. John L. Lubniewski Pres, Chief Executive Officer & Director(age: 61, pay: $510,340)
- Mr. Shaun D. McMeans Senior Vice President of Fin. & Admin., Chief Financial Officer, Sec. and Treasurer(age: 63, pay: $407,070)
- Mr. Byron T. Lawson Senior Vice President & Chief Commercial Officer(age: 50, pay: $349,190)
-
How many employees does HTG Molecular Diagnostics have?
As Jul 2024, HTG Molecular Diagnostics employs 53 workers.
-
When HTG Molecular Diagnostics went public?
HTG Molecular Diagnostics, Inc. is publicly traded company for more then 10 years since IPO on 6 May 2015.
-
What is HTG Molecular Diagnostics's official website?
The official website for HTG Molecular Diagnostics is htgmolecular.com.
-
Where are HTG Molecular Diagnostics's headquarters?
HTG Molecular Diagnostics is headquartered at 3430 East Global Loop, Tucson, AZ.
-
How can i contact HTG Molecular Diagnostics?
HTG Molecular Diagnostics's mailing address is 3430 East Global Loop, Tucson, AZ and company can be reached via phone at 877 289 2615.
HTG Molecular Diagnostics company profile:
HTG Molecular Diagnostics, Inc.
htgmolecular.comExchange:
NASDAQ
Full time employees:
53
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
3430 East Global Loop
Tucson, AZ 85706
Tucson, AZ 85706
CIK: 0001169987
ISIN: US40434H1041
CUSIP: 40434H104
